Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK

HIV Medicine

Volumn 9, Issue 1, 2008, Pages 47-56

  Easterbrook, Phillipa J ^a   Phillips, A N ^b   Hill, T ^b   Matthias, R ^c   Fisher, M ^d   Gazzard, B ^e   Gilson, R ^b   Scullard, G ^f   Johnson, M ^g   Dunn, D T ^c   Orkin, C ^h   Anderson, J ⁱ   Schwenk, A ^j   Leen, C ^k   Sabin, C A ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d Worthing Hospital   (United Kingdom)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

ⁱ HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^j NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^k WESTERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Guidelines; Highly active antiretroviral therapy; Prescribing patterns; Treatment choice

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; DRUG USE; ETHNICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TREND STUDY; UNITED KINGDOM;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 38349051885     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00512.x     Document Type: Article

References (27)

1. Gazzard BG, Moyle GJ, Weber J et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-1092.
2. Gazzard B, Graeme G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
3. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2000; 1: 76-101.
4. British HIV Association. Guidelines for the Treatment of HIV-infected Adults with Antiretroviral Therapy. British HIV Association, London, 2003.
5. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
6. http://www.aidsinfo.nih.gov/.
7. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-265.
8. Brook MG, Curtis H, Johnson MA. Findings from the British HIV Association's national clinical audit of first-line antiretroviral therapy and survey practice and maternity care, 2002. HIV Med 2004; 5: 415-420.
9. Shapiro M, Morton S, McCaffrey D et al. Variations in the care of HIV-infected adults in the United States. JAMA 1999; 281: 2305-2315.
10. Brosgart C, Mitchell T, Coleman R et al. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis 1999; 28: 14-22.
11. Sackoff J, McFarland J, Su S, Bryan E. Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care. J AIDS 1998; 19: 387-392.
12. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115-124.
13. Bassetti S, Battegay M, Furrer H et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J AIDS 1999; 20: 114-119.
14. Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J AIDS 1999; 20: 474-480.
15. Bogart L, Kelly J, Catz S, Sosman J. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J AIDS 2000; 23: 396-404.
16. Pezzotti P, d'Arminio Monforte A, Bugarini R et al. Antiretroviral therapy and HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol 2000; 16: 919-926.
17. PHLS Communicable Disease Surveillance Centre, ICH (London), SCIEH. HIV and AIDS in the UK in 2001. An update: November 2002.
18. Boyd A, Murad S, O'Shea S, de Truiter A, Watson C, Easterbrook PJ. Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London. HIV Med 2005; 6: 59-65.
19. Patterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
20. Stone VE, Hogan JW, Schuman P et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J AIDS 2001; 28: 124-131.
21. Miller LG, Liu H, Hays RD et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Inter Med 2002; 17: 1-11.
22. Bangsberg DR, Hecht FM, Clague H et al. Provider assessment of adherence to HIV antiretroviral therapy. J AIDS 2001; 26: 435-442.
23. Stohr W, Dunn DT, Porter K et al. CD4 cell count and initiation of antiretroviral therapy: Trends in seven UK centres, 1997-2003. HIV Med 2007; 8: 135-141.
24. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J AIDS 2000; 23: 396-404.
25. Avorn J, Solomen DH. Cultural and economic factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Ann Intern Med 2000; 133: 128-135.
26. Soumerai SB, Avorn J. Principles of educational outreach ("academic detailing") to improve clinical decision making. JAMA 1990; 263: 549-556.
27. Lurie N, Rich EC, Simpson DE et al. Pharmaceutical representatives in academic medical centers: Interaction with faculty and housestaff. J Gen Intern Med 1990; 5: 240-243.